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Abstract The Seattle Structural Genomics Center for
Infectious Disease (SSGCID) focuses on the structure
elucidation of potential drug targets from class A, B, and C
infectious disease organisms. Many SSGCID targets are
selected because they have homologs in other organisms
that are validated drug targets with known structures. Thus,
many SSGCID targets are expected to be solved by
molecular replacement (MR), and reﬂective of this, all
proteins are expressed in native form. However, many
community request targets do not have homologs with
known structures and not all internally selected targets
readily solve by MR, necessitating experimental phase
determination. We have adopted the use of iodide ion soaks
and single wavelength anomalous dispersion (SAD)
experiments as our primary method for de novo phasing.
This method uses existing native crystals and in house data
collection, resulting in rapid, low cost structure determi-
nation. Iodide ions are non-toxic and soluble at molar
concentrations, facilitating binding at numerous hydro-
phobic or positively charged sites. We have used this
technique across a wide range of crystallization conditions
with successful structure determination in 16 of 17 cases
within the ﬁrst year of use (94% success rate). Here we
present a general overview of this method as well as several
examples including SAD phasing of proteins with novel
folds and the combined use of SAD and MR for targets with
weak MR solutions. These cases highlight the straightfor-
ward and powerful method of iodide ion SAD phasing in a
high-throughput structural genomics environment.
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The mission of the Seattle Structural Genomics Center for
Infectious Disease (SSGCID) is to provide a blueprint for
structure-guided drug design targeting NIAID class A–C
infectious disease organisms [1, 2]. To meet this goal, the
SSGCID plans to solve more than ﬁve hundred crystal
structures of potential drug targets from infectious disease
organisms over a 5 year period. The Center for Structural
Genomics of Infectious Diseases (CSGID) is a companion
center of SSGCID and maintains a similar mission [3]. For
SSGCID, targets are selected either through an internal
target selection process or are requested by members of the
scientiﬁc community external to the SSGCID consortium.
The majority of internally selected target have a homolog
that is a validated drug target with a known structure,
inferring that in principle most targets may be solved by
molecular replacement (MR). However, in practice, not all
targets solve by MR due to low sequence identity,
numerous sequence homology gaps, conformation changes,
etc. Furthermore, other targets are selected through statis-
tical analysis of sequence-based annotations (Cadag, E.
et al. unpublished) and numerous targets requested by the
scientiﬁc community do not have a homolog with a known
structure, and thus MR is not possible. Given the SSGCID
protein production pipeline that generates native protein
samples, we pursued strategies for obtaining de novo phase
information that utilize native crystals.
Dauter and co-workers described single wavelength
anomalous dispersion (SAD) phasing using iodide ions
[4, 5], a method that has been successfully employed by
others [6–11]. Native crystals are soaked into a solution
containing high concentrations of iodide ions, data is col-
lected in house at Cu Ka radiation where the anomalous
signal for iodide ions is large (Fig. 1), and the phases are
estimated using a SAD experiment [12]. This method is
simple, inexpensive, quick, effective, and was predicted to
be ‘‘particularly suitable for high-throughput crystallo-
graphic and structural genomics projects’’ [8]. Here, we
describe the application of iodide ion SAD phasing to a
number of SSGCID targets that required experimental
phase determination, resulting in sixteen new structures in
1 year. These structures are perhaps the largest collection
of iodide phased structures obtained by a single scientiﬁc
collaboration.
Materials and methods
Protein expression and puriﬁcation
Detailed SSGCID protocols were (for example, see [7, 13,
14]) or will be published elsewhere. Here, we present a
general overview of target cloning, expression, and puri-
ﬁcation. SSGCID targets were cloned using ligation inde-
pendent cloning [15] from genomic DNA when available
or from codon engineered synthetic genes [16, 17]. The
most commonly used SSGCID expression vector
(pAVA0421) encodes an N-terminal histidine afﬁnity tag
followed by the human rhinovirus 3C protease cleavage
Fig. 1 Anomalous scattering
factors for iodide and selenium
across the energy range used in
macromolecular
crystallography. The image was
generated using the University
of Washington X-ray
Anomalous Scattering Server
developed and maintained by
Ethan A. Merritt
(http://skuld.bmsc.
washington.edu/scatter/)
which is based on an earlier
publication [59]
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123sequence (the entire tag is MAHHHHHHMGTLE-
AQTQGPGS-ORF), although other vectors were used as
well. All SSGCID targets were forward and reverse
sequence veriﬁed. Proteins were expressed in E. coli using
BL21 (DE3) R3 Rosetta cells and autoinduction media [18]
in a LEX bioreactor. The cells were pelleted, frozen at
-80C, and puriﬁed at one of three different puriﬁcation
groups, all of which used slightly variant puriﬁcation pro-
tocols reﬂective of different equipment. Brieﬂy, cells were
re-suspended in lysis buffer, sonicated, and clariﬁed by
centrifugation. The proteins were puriﬁed initially by
immobilized metal afﬁnity chromatography. At this point
in the puriﬁcation protocol optional removal of the
expression afﬁnity tag was done for about 60% of all tar-
gets. The protein sample was incubated with 3C protease
followed by a second nickel afﬁnity column in which the
tagless protein of interest appeared in the ﬂow through. All
protein samples used for structure determination described
here were puriﬁed by size exclusion chromatography
equilibrated in 20 mM HEPES pH 7.0, 300 mM NaCl,
2 mM DTT, and 5% glycerol. Fractions containing
pure protein were collected, pooled, concentrated to
*20–30 mg/ml, and stored at -80C prior to crystalliza-
tion experiments.
Crystallization
Crystallization trials were set up using a rational sparse
matrix approach [19] which utilized the JCSG? and PACT
crystallization screens from Emerald BioSystems or
Molecular Dimensions. Sitting drop vapor diffusion crys-
tallization trials were set up at 16C using 0.4 ll of protein
and 0.4 ll of precipitant against 80 ll of reservoir in
Compact Jr 96-well crystallization plates from Emerald
BioSystems. High value targets such as viral, eukaryotic,
fungal or community request targets were set up in addi-
tional crystallization trials such as the ProPlex screen from
Molecular Dimensions, the CSHT, Index, and Salt Rx
screens from Hampton Research or the Wizard Full (I/II)
and Wizard III/IV screens from Emerald BioSystems.
About 9% of targets that entered crystallization trials
yielded a data set with diffraction limits of 2.5 A ˚ resolution
or better straight out of the primary screen. In general,
targets that produced crystals that diffract to better than
*3.5 A ˚ resolution but did not yield data sets suitable for
structure determination were optimized using a 96-well
gradient optimization screen designed and produced using
the E-Wizard screen builder from Emerald BioSystems.
Many targets were screened and optimized using the
Microcapillary Protein Crystallization System (MPCS)
[20, 21] by Emerald BioSystems. SSGCID utilized
numerous salvage pathways such as in situ proteolysis [22]
and seeding techniques [23]. Full crystallization conditions
for each target solved by iodide ion SAD are shown in the
Supporting Information.
Iodide ion soaking
Typically, crystals were soaked for up to 5 min but occa-
sionally as long as 2 h into a solution similar to the pre-
cipitant solution, but which was supplemented with
0.2–1 M iodide ions (Table 1). In general, the cation used
for iodide ion soaks was aligned with the cations of the
crystallization solution, while the anion of the crystalliza-
tion solution was replaced with iodide. Full iodide ion
soaking conditions for each target solved by iodide ion
SAD are shown the Supporting Information.
Data collection and structure determination
Data sets were collected in house using either a Rigaku
007-HF or Rigaku SuperBright FR-E? X-ray generator
with Osmic VariMax HF optics and a Saturn 944 or Saturn
944? CCD detector. Diffraction images are available
through the CSGID web page (www.csgid.org). Data were
reduced with XDS/XSCALE [24] with the Bijvoet pairs
unmerged (i.e., Friedel setting at FALSE). Sites were
located using either phenix.hyss/phenix.autosol [25]o r
SHELXD [26]. The anomalous substructure was reﬁned
and extended, and phases were estimated using PHASER
EP [27] from the CCP4 suite [28] followed by density
improvement in PARROT [29]. Initial models were built
using automated building in BUCCANEER [30], followed
by model extension/rebuilding in ARP/wARP [31]. The
model was reﬁned using SAD reﬁnement with optimization
of the iodide ion occupancy in REFMAC [32]. Final
models were produced after numerous iterative rounds of
manual re-building in Coot [33] and reﬁnement in REF-
MAC [32] using the merged data (i.e., Friedel setting at
TRUE in XSCALE [24]). The correctness of each structure
was examined, validated, and improved using Molprobity
[34, 35].
Results
SAD phasing using iodide ions
In essence, SAD phasing using iodide ions is comprised of
four steps. First, native crystals are soaked into a solution
similar to the precipitant reservoir supplemented with
iodide ions and cryoprotectant if necessary. Second, a data
set is collected in house at Cu Ka radiation where iodide
ions have an anomalous scattering coefﬁcient of 6.9 e
- (f00)
(Fig. 1). Third, the iodide ion sites are located. Fourth,
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123experimental phases are calculated using a SAD experi-
ment. We applied this method over a 1 year period to our
structural genomics structure determination pipeline,
resulting in the determination of 16 new structures from
seventeen targets, a 94% success rate (Tables 1, 2; Fig. 2).
Only ﬁve of the sixteen new structures followed a linear
path to successful structure determination, whereas the
other eleven required reiteration of one or more steps
before successful structure determination.
During the ﬁrst step, we typically soak protein crystals
into a solution containing 1 M iodide ions, although in a
number of cases, the crystals were visibly damaged upon
soaking and/or diffracted poorly. Therefore, the soaking
step was repeated either at lower iodide ion concentrations
or in stepwise fashion across a range of iodide ion con-
centrations until a ﬁnal concentration of 1 M was obtained.
For other targets we started with a more conservative
iodide concentration of 0.2 M which did not result in
successful structure determination (e.g., AnphA.00973.a),
whereas soaking at a higher concentration resulted in
successful structure determination. In one case (PDB ID
3LR5), the protein crystallized in a condition from the
PACT screen which contained 0.2 M NaI, and thus no
soaking was required.
In the data collection step, 360 of data were collected
for all data sets in order to maximize the multiplicity of the
data [8, 36], which should lower the error in the mea-
surement of Bijvoet pairs and thereby increase the accuracy
in the measurement of anomalous signal [37]. During this
step we discovered that the selection of the scaling reso-
lution had an inﬂuence in at least two cases for which
inclusion of all of the data did not lead to a successful
structure determination. For example, cutting the data at
lower resolution limits (2.5 A ˚) led to the successful struc-
ture determination of a putative fructose-1,6-bisphosphate
aldolase from Coccidioides immitis (PDB ID 3PM6),
whereas the data could not be solved at 2.2 A ˚ resolution.
Othershavereportedsimilarresultsforphasecalculationand
main chain building at3 A ˚, followed by reﬁnementat 2.36 A ˚
resolution [8]. The authors of the program SHELXD [26]
indicate that for anomalous-substructure searches truncation
of the data to 3.0–3.5 A ˚ resolution may be critical for some
sub-structure solutions [38]. For these data sets, we did not
observe any evidence for radiation damage, even for crystals
collected with long exposure times.
Unlike selenomethionine-labeled samples, the number of
iodide ion sites is not known a priori. Thus, locating the
heavyatomsitesinthethirdstepisaniterativeprocessusing
Table 1 Crystal structures determined by SSGCID using iodide ion soaks and SAD phasing
PDB ID targetDB ID
a Protein name
b Phasing
resolution (A ˚)
c
Precipitant pH Iodide Soak time
3K9G BobuA.01478.a Plasmid partition protein 2.25 NaCl 6.5 1 M KI 2 9 1h
3KM3 AnphA.00973.a Deoxycytidine triphosphate deaminase 2.1 PEG 3350 8.1 1 M KI 1 h, 15 min
3KW3 BaheA.00339.a Alanine racemase 2.95 PEG 3350 8.5 1 M KI 1 h
3LA9 BupsA.01663.a BpaA trimeric autotransporter adhesin 2.05 PEG 1500 4.0 1 M KI 1 h
3LR0 BupsA.00863.i risS periplasmic domain pH sensor at low pH 1.9 PEG 1000 4.2 1 M KI 1 h
3LR5 BupsA.00863.i risS periplasmic domain pH sensor at neutral pH 2.3 PEG 3350 6.5 0.2 M NaI Co-xtal
3LUZ BaheA.00759.a Extragenic suppressor protein suhB 2.05 PEG 400 7.5 0.75 M KI 1 h
3MD7 BrabA.11339.a b-lactamase like protein 2.0 PEG 3350 8.6 0.25 M KI 5 min
3MEN BupsA.10154.b Acetylpolyamine aminohydrolase 1.9 (NH4)2SO4 6.5 0.2 M NaI 1 h
3NJB MysmA.00358.i Enoyl-CoA hydratase 2.2 PEG 3350 8.5 0.4 M NaI 10 min
3O2E BaboA.10365.a Bol-A like protein 1.95 (NH4)2SO4 6.5 1.0 M NaI 4 9 5 min
3OIB MysmA.00247.b Acyl-CoA dehydrogenase 2.1 PEG 3350 8.5 0.5 M NaI 2 min
3OL3 MysmA.17112.a Ortholog of community request target Rv0543c 1.95 PEG 400 7.5 1 M NaI 4 min
3P96 MyavA.01155.a Phosphoserine phosphatase SerB 2.75 PEG 6000 6.0 1 M KI 4 min
3PFD MythA.00185.b Acyl-CoA dehydrogenase 2.1 PEG 8000 4.2 1 M NaI 20 min
3PM6 CoimA.00345.a Putative fructose-1,6-bisphosphate aldolase 2.5 PEG 8000 5.0 1 M NaI 15 min
a Organism identiﬁers correspond to the ﬁrst four letters of the targetDB ID. Anph identiﬁes Anaplasma phagocytophilum, Babo identiﬁes
Babesia bovis, Bahe identiﬁes Bartonella henselae, Bobu identiﬁes Borrelia burgdoerferi, Brab identiﬁes Brucella melitensis (biovar abortus),
Bups identiﬁes Burkholderia pseudomallei, Coim identiﬁes Coccidioides immitis, Myav identiﬁes Mycobacterium avium, Mysm identiﬁes
Mycobacterium smegmatis, and Myth identiﬁes Mycobacterium thermoresistibile
b BupsA.01663.a [7] and BupsA.00863.i were community request targets for which no homologous protein structure was available in the PDB;
neither of these targets contain internal methionine residues
c The resolution limits of the native data sets were 2.05 A ˚ for 3KW3, 1.27 A ˚ for 3MD7, and 2.05 A ˚ for 3P96
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123one or more computational programs. We found this step to
be the most challenging for targets with a large asymmetric
unit because the programs compare the sites from multiple
solutions as a quality indicator. For example, acyl-CoA
dehydrogenase from Mycobacterium thermoresistibile
(PDB ID 3PFD) contained over one hundred iodide ions in
theﬁnalmodel(allofwhichhadelectrondensityabove5rin
an anomalous difference Fourier map). Challenging the
programstoﬁnd10sitesonlyreturned1or2sites,becauseit
could not ﬁnd the same 10 sites out of more than 100 total
sites. However, challenging the programs to ﬁnd a higher
number of sites resulted in a successful structure determi-
nation. In contrast, crystals of the trimeric autotransporter
adhesin BpaA from Burkholderia pseudomallei were twin-
ned, and thus the number of sites was kept to a minimum to
avoid selecting strong sites from the minor twin fraction [7].
In that case, selecting six to ten sites yielded low quality
experimental electron density maps, whereas selecting only
two or four sites led to successful structure determination,
despite nine iodide ions in the ﬁnal model. Based on the
number of amino acids per iodide ion for successfully
determinedstructures(Table 2),werecommendchallenging
theprogramstoﬁndoneiodideionpertwentyaminoacidsof
the projected scattering mass.
The fourth step, SAD phase calculation, is also an iter-
ative process. After density improvement, the experimental
electron density maps were inspected for tertiary structure
such as a-helices and b-sheets as well as solvent channels
and correlation between iodide sites and the experimental
electron density. Any iodide sites which did not correlate
with the experimental electron density maps were elimi-
nated and the phases were re-calculated with only the real
iodide ion sites. This reiteration often improved the phase
quality and consequently resulted in more extensive auto-
mated structure building. For targets with a weak MR
solution from which a structure could not be determined
directly, the weak MR solution could be incorporated into
the SAD experiment. This combined use of SAD and MR
has been successful in four cases (Table 2 and see below).
In these cases, the increased number of sites indentiﬁed by
combined SAD/MR could be used in a subsequent SAD
experiment with no MR component to calculate the phases.
Success with a diverse set of proteins, crystallization
conditions, and crystal forms
The proteins used in these experiments derived from Gram
negative bacteria, fungi, and eukaryotes (Table 1).
Table 2 Crystallographic and phasing statistics for iodide SAD phased SSGCID structures
PDB ID Phasing
resolution (A ˚)
Space group Multiplicity
a SigAno
b Residues
in AU
Solvent
content (%)
Iodide sites
c FOM
d Method
3K9G 2.25 P43212 12.5 1.43 1 9 267 51 2/12 0.45 SAD
3KM3 2.1 H3 5.6 1.16 2 9 206 42 13/16 0.24 SAD
3KW3 2.95 C2 3.8 1.26 2 9 372 45 4/0 0.29 SAD/MR
3LA9 2.05 H3 5.4 2.08 1 9 178 29
e 4/9 0.49 SAD
3LR0 1.9 P3221 11.2 2.33 1 9 123 46 6/6 0.44 SAD
3LR5 2.3 P212121 3.6 0.99 2 9 123 43 4/5 0.39 SAD
3LUZ 2.05 P21 3.8 1.22 2 9 267 37 6/13 0.50 SAD/MR
3MD7 2.00 C2221 6.5 1.34 2 9 272 40 11/0 0.49 SAD
3MEN 1.9 P212121 6.8 1.24 4 9 341 43 24/35 0.41 SAD
3NJB 2.2 I23 10.9 1.27 2 9 333 59 9/50 0.39 SAD
3O2E 1.95 P41212 10.3 1.70 1 9 90 25 5/9 0.53 SAD
3OIB 2.1 C2 3.7 1.78 2 9 403 48 15/50 0.55 SAD
3OL3 1.95 P212121 6.6 1.91 2 9 103 51 9/21 0.43 SAD
3P96 2.75 I222 7.7 1.70 1 9 418 53 15/0 0.41 SAD
3PFD 2.1 P21 3.7 1.19 4 9 389 48 8/109 0.53 SAD/MR
3PM6 2.5 P21 3.8 1.64 2 9 302 46 5/31 0.46 SAD/MR
a Overall multiplicity for anomalous scaled data; multiplicity for merged data is ca. twofold higher
b SigAno is the mean anomalous difference in units of its estimated standard deviation (|F
? - F
-|/r)[ 24]
c The number of iodide sites input into Phaser EP [27], followed by the number of iodide sites in the ﬁnal model. For 3KW3, 3MD7 and 3P96
only the high-resolution native data was deposited into the PDB, and thus the ﬁnal model contained no iodide ion sites
d Overall Figure of Merit (FOM) from Phaser EP [27] prior to density modiﬁcation
e The solvent content was calculated based on the full length tagged protein. This protein only crystallized using in situ proteolysis with
chymotrypsin [22], and thus, the true solvent content is likely higher [7]
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123Examination of the crystallization and soaking conditions
for the sixteen structures determined using iodide ion SAD
phasing revealed a number of different precipitants from
low to high molecular weight polyethylene glycols (PEG
400 to 8,000) and a variety of different salts including
ammonium sulfate and sodium chloride (Table 1 and
Supporting Information). These examples represent a broad
distribution of precipitants common to a rational sparse
matrix approach [19]. In addition, crystals grew and were
soaked over a wide pH range from 4.0 to 8.6 (Table 1),
spanning nearly the entire range of commonly used crys-
tallization screens. The space groups varied from low
symmetry (monoclinic, C2 and P21) to high symmetry
(cubic, I23) and from the most commonly observed space
group P212121 to rare space groups such as I23 (Table 2).
The number of residues in the asymmetric unit varied from
less than 100 to more than 1,500 (Table 2). The packing
density [39] ranged from a solvent content of 25%
(Vm = 1.64 A ˚ 3/Da) to 59% (Vm = 3.04 A ˚ 3/Da), spanning
the range commonly observed for protein crystals. The
phasing resolution ranged from 1.9 to 2.95 A ˚ with most
about 2.1 A ˚; the native data sets for these structures ranged
from 1.27 to 2.3 A ˚ resolution (Table 1). Finally, the pro-
teins themselves are quite varied in structure and function
(Table 1; Fig. 2). For example, these structures contain
both novel (3LA9 [7]) and previously observed folds. The
Fig. 2 Crystal structures determined by SSGCID using iodide ion soaks and SAD phasing
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123tertiary structure ranged from all a-helical (3OL3) to nearly
all b-sheet (3KM3). Different oligomeric states were
observed from monomeric to tetrameric. Apo and ligand
bound states were also observed. In all, these proteins,
crystallization conditions, crystal forms, and diffraction
properties are reﬂective of the SSGCID structure determi-
nation pipeline in general.
Types of iodide ion sites
The sixteen structures described here contained over 350
iodide ion sites combined, representing a wide variety of
iodide ion-protein interactions (Fig. 3). These sites can be
divided into several categories. As expected, we observed
binding of iodide ions near positively charged surface
residues, mostly arginine, lysine and to a lesser extent
histidine residues. Interestingly, we observed a number of
cases where the iodide ion displaced a surface exposed
negatively charged residue relative to the native structure,
in order to interact with a positively charged residue. A
second type of interaction we observed was the binding of
iodide ions to hydrophobic patches, such as binding prox-
imal to proline, methionine, or aromatic side-chains.
Again, in some cases, we observed displacement of a side
chain to an alternative rotamer conformation, relative to the
native structure, to accommodate the iodide ion in prox-
imity to a hydrophobic region. A third type of interaction,
which was one of the most frequently observed, involved
interactions with backbone amides via packing off the
O-C-N plane or binding to solvent exposed amide nitrogen
atoms. In the latter case, the iodide ion resided approxi-
mately 3.5–3.7 A ˚ away from the amide nitrogen atom. A
fourth type of interaction was the binding of iodide ions in
the vicinity of H-bond forming residues such as glutamine
and asparagine residues, and to a lesser extent threonine
and serine residues. Surprisingly, this category included
Fig. 3 Types of iodide ion binding sites. a Arginine-iodide ion
interaction network on the surface of MysmA.17112.a (PDB ID
3OL3), a putative uncharacterized protein from Mycobacterium
smegmatis and an ortholog of community request protein My-
tuD.17112.a, Rv0543c from Mycobacterium tuberculosis (PDB ID
2KVC [60]) b Iodide ions binding along an a-helix of Co-
imA.00345.a, a putative fructose-1,6-bisphosphate aldolase from
Coccidioides immits (PDB ID 3PM6). Iodide ion IA forms a possible
anion–cation interaction with His21, while forming an interaction
with the side chain hydroxyl of Thr20 (3.3 A ˚), an amide interaction
with Thr16 and a hydrophobic interaction with Phe17. Iodide ion IB
forms hydrophobic interactions with the side chains of Met298 and
Val14, while packing off the amide of Pro13-Val14. c Iodide ion
binding to the periplasmic domain of the risS pH sensor histidine
kinase from Burkholderia pseudomallei (BupsA.00863.i, a commu-
nity request target, PDB ID 3LR0). The iodide ion forms an
interaction with the backbone amide nitrogen of Asp122 (3.5 A ˚) while
forming another interaction with the side chain of Ser119 (3.4 A ˚) and
packing against two b-sheets. d Iodide ion binding off reduced ﬂavin
adenine dinucleotide (FADH2) in the crystal structure of an acyl-CoA
dehydrogenase from M. thermoresistibile (MythA.00185.b, PDB ID
3PFD). An unbiased |Fo| - |Fc| map calculated from a model lacking
the cofactor is shown in green mesh contoured at 3.0 r. For each
panel iodide ions are shown as magenta spheres and an anomalous
difference Fourier map is shown in magenta mesh contoured at 5.0 r
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123aspartic acid and glutamic acid residues for crystals
obtained at low pH (4.0–4.2), in which the carboxylic acid
side chains are expected to be protonated. Of course, many
iodide ions made multiple types of interactions with the
protein, such as residing next to the side chain of an
arginine residue while packing off an a-helix (Fig. 3).
Interestingly, we observed iodide ion binding off the uri-
dine-like ring of reduced riboﬂavin adenine dinucleotide
(FADH2) in the M. thermoresistibile acyl-CoA dehydro-
genase crystal structure solved at 2.1 A ˚ resolution (PDB ID
3PFD, Fig. 3d), an interaction which was observed in all
four protomers of the biological tetramer observed in the
asymmetric unit.
Case study 1: BolA-like protein from Babesia bovis
Babesia bovis is a tick-borne parasitic protozoan of the
phylum apicomplexa. It primarily infects cattle causing
babesiosis, a ‘malaria-like’ hemolytic anemia, although
occasionally infecting humans as well [40]. SSGCID target
BaboA.10365.a is a BolA-like protein from B. bovis.
Although the function is not fully understood, the
expression of a BolA-like protein in Escherichia coli was
reported to be linked to a change in morphology,
suggesting a function during cell division [41].
BaboA.10365.a is a small, 86-residue protein. Sequence
database searches revealed BolA-like proteins from Plas-
modium falciparum (51% sequence identify, PDB ID
2KDN; Buchko, G.W. et al. unpublished), from Mus
musculus (43% sequence identity, 1V9J [42]) and from
E. coli (34% sequence identity, 2HDM [43]) as closest
sequence homolog with a known structure. Unfortunately,
all of these solution NMR structures proved unsuitable for
MR [44]. BaboA.10365.a could be crystallized in a
tetragonal space group (P41212) with a small unit cell
(a = b = 66 A ˚, c = 35 A ˚) using ammonium sulphate as
the precipitant. The crystals lost order when the environ-
ment was changed too quickly, for example by introducing
iodide for phasing or ethylene glycol as cryoprotectant.
When the concentration of iodide and cryoprotectant were
simultaneously increased in several steps, well diffracting
crystals could be prepared. A highly redundant data set
with resolution limits of 1.95 A ˚ revealed strong anomalous
signal that extended to full resolution (SigAno 1.70,
anomalous correlation coefﬁcient 59%). Four anomalous
sites were located in Phenix [25] and extended to nine
anomalous sites in PHASER EP [27]. After density mod-
iﬁcation with PARROT [29], ARP/wARP [31] could build
77 residues. While considering both enantiomorphic space
groups, the ﬁrst model of BaboA.10365.a was obtained
literally minutes after data collection and data reduction
had ﬁnished. A post-hoc analysis of homologous structures
(Fig. 4) using the SSM/PDBeFOLD server [45] revealed
that sequence homologs have enough structural diversity,
rendering them unsuitable for MR. The closest structural
homolog is the BolA-like protein from M. musculus (1V9J,
[42]) with a RMSD of 1.9 A ˚ over 79 aligned residues. The
closest sequence homolog is the BolA-like protein from
P. falciparum (2KDN, Buchko, G.W. et al. unpublished),
which is less structurally similar: RMSD of 2.6 A ˚ over 76
aligned residues. The crystal structure of the BolA-like
protein from B. bovis described here (PDB ID 3O2E) is the
ﬁrst crystal structure of a BolA-like protein, whereas all
other BolA-like protein structures have been solved by
solution NMR (Plasmodium falciparum PDB ID 2KDN,
Buchko, G.W. et al. unpublished; Mus musculus 1V9J
[42]; E. coli 2HDM [43]).
Case study 2: phosphoserine phosphatase SerB
from Mycobacterium avium
OrthologsfromseveralMycobacteriumspecies(M.abscessus,
M. avium, M. bovis, M. leprae, M. marinum, M. paratuber-
culosis, M. smegmatis, M. ulcerans,a n dM. thermoresistibile)
are used in a salvage pathway to rescue M. tuberculosis
targets that fail at some stage of the SSGCID structure
determination pipeline. Phosphoserine phosphatase SerB
catalyzes the reaction of 3-phosphoserine to L-serine
(EC:3.1.3.3), the ﬁnal step in the biosynthesis of ser-
ine. SerB from M. tuberculosis (targetDB MytuD.01155.a)
failed to produce diffraction quality crystals, and thus the
M. avium ortholog Ma SerB was entered into the SSGCID
pipeline. Ma Ser yielded a 2.05 A ˚ resolution native data set.
Fig. 4 Overlay of NMR solution structures of BolA-like proteins
from M. musculus (gray, PDB ID 1V9J [42]), P. falciparum
(magenta, Buchko, G.W. et al. unpublished) and the crystal structure
of a BolA-like protein from B. bovis solved by iodide ion SAD
(green, PDB ID 3O2E). Iodide ions are shown as green spheres. For
simplicity only the ordered regions are shown
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123The closest homologous structure in the PDB contained
44% sequence identity over less than half the Ma SerB
sequence with no homologous structure for the remainder of
the protein. Unsurprisingly, MR failed. Crystals used for
iodide phasing grew in 20% PEG 3350 and 0.2 M magne-
sium formate. For the ﬁrst attempt, a crystal was soaked into
a mixture of 75% precipitant and 25% KI-saturated ethylene
glycol (ﬁnal [KI] & 0.5 M), but did not yield sufﬁcient
anomalous signal for structure solution (SigAno 1.34 for all
reﬂections to 3.15 A ˚ resolution). A second crystal was
soaked into 20% PEG 3350, 0.1 M magnesium formate,
1.0 M KI, and 25% ethylene glycol for 4 min, followed by
ﬂash-cooling in liquid nitrogen and data collection, result-
ing in enhanced anomalous signal (SigAno 1.70). The
structurewas solved at 2.75 A ˚ resolution using 15 iodide ion
sites located using phenix.autosol [25], followed by auto-
mated building and reﬁnement using the high resolution
data set.
Like other SerB homologs, Ma SerB is a homodimer
with Mg
2? and Cl
- bound in the active site. By homology,
Mg
2? is a required cofactor, and the chloride ion occupies
approximately the predicted phosphate position. Unusual
for SerB enzymes, Ma SerB consists of three domains
(Fig. 5), which is reﬂected in the low sequence homol-
ogy of Ma SerB with other SerB enzymes. The ﬁrst
domain (residues 1–85) and second domain (residues
97–175) adopt the babbab ferredoxin fold, and there is a
domain swap between the two monomers of the dimer
via the long linker region between these two domains
(Fig. 2). The sequence identity between domains 1 and 2
is only 25%, but they superimpose with RMSD 1.4 A ˚.
Domain 3 (residues 182–400) represents the conserved
core of the enzyme, and consists of a 6-stranded parallel
beta sheet, resembling a Rossman fold with a set of
extra helixes and anti-parallel beta strands inserted. Other
phosphoserine phosphatases overlap well on domain 3,
and some, such as that from Vibrio cholerae (PDB ID
3N28, Patskovsky, Y. et al. unpublished) match domain
2 poorly (Fig. 5). The N-terminal domain 1 of Ma SerB
appears to be unique.
Case study 3: putative fructose-1,6-bisphosphate
aldolase from Coccidioides immitis
Coccidioides immitis is a pathogenic fungus which causes
the potentially fatal systemic disease coccidioidomycosis
[46], also known as Valley Fever because it was thought
to originate in the San Joaquin Valley in California. Many
open reading frames from the genome of Coccidioides
immitis [47] are annotated as putative uncharacterized
protein, but contain sequence homology to proteins
of known function. One such case is the SSGCID target
CoimA.00345.a, which is annotated as a putative
uncharacterized protein. CoimA.00345.a shares 35%
sequence identity with 11% gaps over 70% of its
sequence with fructose-1,6-bisphosphate aldolase from
Giardia lamblia [48]. We obtained a 2.05 A ˚ resolution
native data set of CoimA.00345.a. Despite numerous
attempts, we were unable to solve this target via MR,
although we noted weak but plausible rotation (RFZ 6.0)
and translation scores (TFZ 3.8) in Phaser MR [27].
Soaking with 0.5 M NaI for 2 min yielded a 2.4 A ˚ res-
olution data set with weak anomalous signal (SigAno
0.91, 14% anomalous correlation) from which we were
unable to solve the structure using a SAD experiment.
Fig. 5 Sequence alignment and crystal structures of phosphoserine
phosphatase SerB from Vibrio cholera (bottom sequence, gray
ribbons, PDB ID 3N28, Patskovsky, Y. et al. unpublished) and
Mycobacterium avium solved by iodide ion SAD (top sequence, green
ribbons, PDB ID 3P96). For simplicity, only one monomer of the
biological dimer is shown in each case. Domains 1, 2, and 3 of Ma
SerB correspond to residues 1–85, 97–175, and 182–400, respectively
SAD phasing using iodide ions 91
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for 15 min. Attempts to solve the structure at 2.2 A ˚ res-
olution failed, despite modest anomalous signal (SigAno
1.39, 52% anomalous correlation overall; 0.86, 7% in the
last shell). The resolution limits were trimmed to 2.5 A ˚
resolution (SigAno 1.64, 62% anomalous correlation
overall; 0.96, 17% in the last shell), and despite locating
ﬁve sites, again we were unable to solve the structure.
Combining the weak MR solution and the anomalous sites
[49] in Phaser EP [27], we obtained a total of 31 heavy
atom sites (3 of which were incorrect), a FOM of 0.46,
and clearly interpretable experimental electron density
maps. Although the two fructose-1,6-bisphosphate aldol-
ases from the eukaryote G. lamblia and the fungi
C. immitis clearly share the same fold (Fig. 6), there are
numerous gaps and deletions in the protein sequence and
structure as well as considerable conformational hetero-
geneity, which results in an RMSD of 1.79 A ˚ for aligned
residues, a value which exceeds the common threshold for
success by MR [44].
Discussion
Experimental phasing in a structural genomics
environment
The most common method for de novo structure determi-
nation utilizes replacement of methionine residues with
selenomethionine and multiwavelength anomalous disper-
sion (MAD) or SAD experiments [50]. For success, this
method requires the completion of several steps. First, the
protein of interest must contain internal methionine resi-
dues or have them engineered into the protein sequence.
Second, a protein sample must be expressed using minimal
media supplemented with selenomethionine, a process that
often results in lower protein yields than native protein
expression. Third, the protein sample must be puriﬁed and
crystallized, a process that often requires re-optimization
relative to the native protein due to the increased lipo-
philicity of selenomethionine labeled proteins. Finally, this
method requires synchrotron radiation, preferably at a
tunable beamline, although several monochromatic beam-
lines such as ALS 5.0.1 and 5.0.3 have recently been
adjusted to an energy setting reﬂective of the selenium K
edge [51]. As a consequence of the numerous additional
steps required to solved structures by selenomethionine
SAD/MAD phasing, there is typically a lag time of several
months or more between obtaining native crystals that
diffract to high resolution and solving the structure.
One of the major goals of the Protein Structure Initiative
(PSI) was the elucidation of novel protein folds [52]. Thus,
for many PSI centers all of the protein samples destined
for crystallography were expressed as selenomethionine-
labeled proteins [53] with the intention of solving the
structures by traditional selenomethionine-based SAD or
MAD experiments. Although thousands of structures have
been solved using this method [50], there is additional cost
in reagents and time associated with solving structures via
this method in comparison with structures that may be
solved by MR. Given the PSI major goal of obtaining novel
protein folds, the additional cost is certainly justiﬁable.
Rather than investigate new folds, the goal of the SSGCID
is to determine structures of potential drug targets from
infectious disease organisms. Given that most protein
structures are expected to be solved by MR, all proteins are
expressed in native form in an effort to lower costs and
improve success rates; native proteins generally express at
higher levels and consequently crystallize at higher rates
than selenomethionine-labeled proteins. However, in
practice not all structures are solved by MR, and thus the
phases for these targets must be determined experimen-
tally. We could have adopted the selenomethionine-based
method; however, the SSGCID pipeline generates native
crystals, and thus, we decided to proactively explore
Fig. 6 Sequence alignment and crystal structures of fructose-1,6-
bisphosphate aldolases from Giardia lamblia (bottom sequence, gray
ribbons, PDB ID 2ISV [48]) and Coccidioides immitis solved by
combined iodide ion SAD and MR (top sequence, green ribbons,
PDB ID 3PM6). Iodide ions are shown as magenta spheres and the
catalytic zinc ions are shown as gray spheres. Anomalous difference
Fourier maps are shown in magenta mesh contoured at 5.0 r
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123phasing options that use native crystals rather than waiting
months to obtain selenomethionine-labeled crystals.
There are a number of methods for heavy atom labeling
of native crystals and structure determination by isomor-
phous replacement and/or anomalous scattering methods
[54]. Methods developed within the past 10 years include
radiation induced phasing [55], covalent iodination [56],
non-covalent binding of an iodinated ‘‘magic triangle’’
[57], and bromine or iodide ion soaking and SAD or single
isomorphous replacement with anomalous scattering
(SIRAS) [4, 5]. For SSGCID, we wanted to use a method
that did not require toxic compounds such as mercury or
platinum, and which would be applicable over a wide range
of SSGCID targets. Therefore, we selected the use of
iodide ion soaking and SAD experiments [4, 5], which was
predicted to be particularly suitable for structural genomics
projects [8]. Over the past year, we applied this method to
seventeen structural genomics targets and determined six-
teen new structures. This method failed in only one case
(URE3-BP from Entamaeba histolytica, targetDB ID En-
hiA.01648.a, a community request target [58]), for which
MR, selenomethionine-based SAD/MAD, bromide ion
SAD/MAD, La
3? SIRAS, K2PtCl4 SIRAS, HgCl2 SIRAS,
tungstate SAD, Cs
? SAD, and sulfur SAD have also failed
thus far.
Why SAD phasing using iodide ions works
There are many reasons for the high success rate of
structure determination using iodide ion soaks and SAD
phasing by SSGCID. From the technical vantage point, the
modern in house X-ray generators, optics and detectors
used by SSGCID (see section ‘‘Materials and methods’’)
has had a signiﬁcant impact on the success of this method.
Using previous generation in house X-ray equipment, for
many targets it would have taken 10 days to collect a full
360 data set required for high multiplicity, whereas the
current generation in house equipment (approaching 10
11
Xrays/s mm
2) rivals second generation synchrotrons in ﬂux
and data collection times, ranging from 10 min to a few
hours. However, some synchrotron beamlines such as ALS
5.0.2 [51] have nearly as much ﬂux at low energy where
the anomalous signal for iodide is high (e.g., 1.54 A ˚)a sa t
higher energy (e.g., 1 A ˚). Thus, this method is not exclu-
sive to in house data collection, although one must consider
the effects of radiation decay on the data collection
parameters [37]. In addition to improved hardware, current
software such as Phenix [25] and Phaser EP [27] has had a
signiﬁcant impact on the success by making the identiﬁ-
cation of anomalous sites rapid and accurate.
From the chemical vantage point, there are two major
reasons for the success of this method by SSGCID. First,
SSGCID targets are puriﬁed in moderately high salt con-
centrations (0.3 M NaCl), implying that SSGCID proteins
that crystallize were selected for stability in moderately
high salt concentrations. Thus, soaking into 0.2–1 M iodide
ions is unlikely to dramatically damage many of these
crystals. Second, at high concentrations, soft ions such as
iodides bind weakly to numerous sites on the surface of
proteins. These sites include binding to positively charged
residues, hydrophobic sites, amides, protonated residues,
etc. These types of interactions form regardless of crys-
tallization conditions including precipitant identity and pH,
or even dramatically different tertiary or quaternary protein
structure. These two features coupled with the high
anomalous signal of iodide at a wavelength of 1.5418 A ˚
(f00 = 6.9 e
- for iodide), which is higher than the theoretical
value of selenium at synchrotron radiation (f00 = 3.8 e
- at
0.97946 A ˚; white line effects at the selenium peak may
push f00 higher), are keys to the success of this method.
Conclusions
SAD phasing with iodide ions was applied to a diverse set
of structural genomics protein targets from bacterial,
fungal, and eukaryotic organisms, and over a wide range
of crystallization conditions common to most sparse
matrix approaches. The net result is rapid, effective, low
cost structure solution that addresses a bottleneck other-
wise created by the secondary preparation of selenome-
thionine-labeled crystals for a structural genomics
pipeline that normally generated native protein samples
and crystals. Although this method is not new, this is the
ﬁrst time it has been used in a high-throughput structural
genomics environment. As a result, we obtained sixteen
new structures in 1 year, providing a wealth of informa-
tion with regard to the structural underpinnings of iodide
ion SAD phasing. Moreover, these cases demonstrate the
general applicability of this method for de novo structure
determination.
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